Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India
IntroductionThere is a scarcity of data from India on the impact of cell of origin (COO) on outcomes of diffuse large B-cell lymphoma (DLBCL). This study was conducted to evaluate the impact of COO on outcomes of DLBCL patients treated with uniform rituximab, cyclophosphamide, doxorubicin, vincristi...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6b906145494245c4afbab335ad86a59e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6b906145494245c4afbab335ad86a59e |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6b906145494245c4afbab335ad86a59e2021-12-02T10:54:13ZImpact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India2234-943X10.3389/fonc.2021.770747https://doaj.org/article/6b906145494245c4afbab335ad86a59e2021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.770747/fullhttps://doaj.org/toc/2234-943XIntroductionThere is a scarcity of data from India on the impact of cell of origin (COO) on outcomes of diffuse large B-cell lymphoma (DLBCL). This study was conducted to evaluate the impact of COO on outcomes of DLBCL patients treated with uniform rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (RCHOP) protocol.Materials and MethodsThis retrospective analysis included patients who received uniform RCHOP chemoimmunotherapy during the study period (2014–2020) at the Department of Medical Oncology at All India Institute of Medical Sciences (AIIMS), New Delhi, India. The patients were classified as germinal center B-cell like (GCB) or activated B-cell (ABC) type using the Hans classification.ResultsFour hundred seventeen patients with median age of 48 years (range, 18–76) and a male-female ratio of 2:1 were included in the analysis. B symptoms and bulky disease were seen in 42.9% and 35.5%. Extranodal involvement was seen in 50.8% of cases. ECOG performance status (0-2) was present in 65%, and 51% presented with advanced disease. GCB subtype was seen in 43%, and 47% were ABC type. Low- and intermediate-risk international prognostic index (IPI) score was seen in 76% of cases. The overall response rate to RCHOP was 85.8%, including a complete response rate of 74.8%. After a median follow-up of 30 months, the 3-year event-free survival (EFS) and overall survival (OS) were 80% and 88%, respectively. The presence of B symptoms and poor ECOG performance status (3-4) was associated with inferior CR rate. Low albumin (p < 0.001), age >60 years (p = 0.001), bulky disease (p < 0.001), and extranodal involvement (p = 0.001) were associated with inferior EFS, whereas a high IPI risk score was associated with an inferior OS (p < 0.001). EFS and OS were not significantly different between the GCB and ABC subtypes. Grade III/IV anemia, neutropenia, and thrombocytopenia were seen in 7.6%, 13.6%, and 2.7% of patients, respectively. Febrile neutropenia was seen in 8.9% of patients, and there were four treatment-related deaths.ConclusionsCell of origin for DLBCL has no impact on CR, EFS, and OS if patients are appropriately treated with standard doses and frequency of RCHOP. RCHOP is well tolerated in our patients, and results are comparable with the Western data.Ajay GogiaSukesh NairShalabh AroraLalit KumarAtul SharmaRitu GuptaAhitagni BiswasSaumyaranjan MallickFrontiers Media S.A.articlesurvivaldiffuse large B-cell lymphoma (DLBCL)rituximabCHOP (R-CHOP)Indiacell of originNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
survival diffuse large B-cell lymphoma (DLBCL) rituximab CHOP (R-CHOP) India cell of origin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
survival diffuse large B-cell lymphoma (DLBCL) rituximab CHOP (R-CHOP) India cell of origin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ajay Gogia Sukesh Nair Shalabh Arora Lalit Kumar Atul Sharma Ritu Gupta Ahitagni Biswas Saumyaranjan Mallick Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India |
| description |
IntroductionThere is a scarcity of data from India on the impact of cell of origin (COO) on outcomes of diffuse large B-cell lymphoma (DLBCL). This study was conducted to evaluate the impact of COO on outcomes of DLBCL patients treated with uniform rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (RCHOP) protocol.Materials and MethodsThis retrospective analysis included patients who received uniform RCHOP chemoimmunotherapy during the study period (2014–2020) at the Department of Medical Oncology at All India Institute of Medical Sciences (AIIMS), New Delhi, India. The patients were classified as germinal center B-cell like (GCB) or activated B-cell (ABC) type using the Hans classification.ResultsFour hundred seventeen patients with median age of 48 years (range, 18–76) and a male-female ratio of 2:1 were included in the analysis. B symptoms and bulky disease were seen in 42.9% and 35.5%. Extranodal involvement was seen in 50.8% of cases. ECOG performance status (0-2) was present in 65%, and 51% presented with advanced disease. GCB subtype was seen in 43%, and 47% were ABC type. Low- and intermediate-risk international prognostic index (IPI) score was seen in 76% of cases. The overall response rate to RCHOP was 85.8%, including a complete response rate of 74.8%. After a median follow-up of 30 months, the 3-year event-free survival (EFS) and overall survival (OS) were 80% and 88%, respectively. The presence of B symptoms and poor ECOG performance status (3-4) was associated with inferior CR rate. Low albumin (p < 0.001), age >60 years (p = 0.001), bulky disease (p < 0.001), and extranodal involvement (p = 0.001) were associated with inferior EFS, whereas a high IPI risk score was associated with an inferior OS (p < 0.001). EFS and OS were not significantly different between the GCB and ABC subtypes. Grade III/IV anemia, neutropenia, and thrombocytopenia were seen in 7.6%, 13.6%, and 2.7% of patients, respectively. Febrile neutropenia was seen in 8.9% of patients, and there were four treatment-related deaths.ConclusionsCell of origin for DLBCL has no impact on CR, EFS, and OS if patients are appropriately treated with standard doses and frequency of RCHOP. RCHOP is well tolerated in our patients, and results are comparable with the Western data. |
| format |
article |
| author |
Ajay Gogia Sukesh Nair Shalabh Arora Lalit Kumar Atul Sharma Ritu Gupta Ahitagni Biswas Saumyaranjan Mallick |
| author_facet |
Ajay Gogia Sukesh Nair Shalabh Arora Lalit Kumar Atul Sharma Ritu Gupta Ahitagni Biswas Saumyaranjan Mallick |
| author_sort |
Ajay Gogia |
| title |
Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India |
| title_short |
Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India |
| title_full |
Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India |
| title_fullStr |
Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India |
| title_full_unstemmed |
Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India |
| title_sort |
impact of cell-of-origin on outcome of patients with diffuse large b-cell lymphoma treated with uniform r-chop protocol: a single-center retrospective analysis from north india |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/6b906145494245c4afbab335ad86a59e |
| work_keys_str_mv |
AT ajaygogia impactofcelloforiginonoutcomeofpatientswithdiffuselargebcelllymphomatreatedwithuniformrchopprotocolasinglecenterretrospectiveanalysisfromnorthindia AT sukeshnair impactofcelloforiginonoutcomeofpatientswithdiffuselargebcelllymphomatreatedwithuniformrchopprotocolasinglecenterretrospectiveanalysisfromnorthindia AT shalabharora impactofcelloforiginonoutcomeofpatientswithdiffuselargebcelllymphomatreatedwithuniformrchopprotocolasinglecenterretrospectiveanalysisfromnorthindia AT lalitkumar impactofcelloforiginonoutcomeofpatientswithdiffuselargebcelllymphomatreatedwithuniformrchopprotocolasinglecenterretrospectiveanalysisfromnorthindia AT atulsharma impactofcelloforiginonoutcomeofpatientswithdiffuselargebcelllymphomatreatedwithuniformrchopprotocolasinglecenterretrospectiveanalysisfromnorthindia AT ritugupta impactofcelloforiginonoutcomeofpatientswithdiffuselargebcelllymphomatreatedwithuniformrchopprotocolasinglecenterretrospectiveanalysisfromnorthindia AT ahitagnibiswas impactofcelloforiginonoutcomeofpatientswithdiffuselargebcelllymphomatreatedwithuniformrchopprotocolasinglecenterretrospectiveanalysisfromnorthindia AT saumyaranjanmallick impactofcelloforiginonoutcomeofpatientswithdiffuselargebcelllymphomatreatedwithuniformrchopprotocolasinglecenterretrospectiveanalysisfromnorthindia |
| _version_ |
1718396474241318912 |